A series of N1-heterocyclic pyrimidinediones were extensively evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Inhibitor 1 is active against NNRTI-resistant viruses including RT mutant K103N. The co-crystal structure of inhibitor 1 with HIV-1 RT revealed that H-bonds are formed with K101 and K103. Efforts to improve the suboptimal pharmacokinetic profile of 1 resulted in the discovery of compound 13, which represents the lead compound in this series with improved pharmacokinetics and similar potency as inhibitor 1.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2010.01.086 | DOI Listing |
Publication Analysis
Top Keywords
n1-heterocyclic pyrimidinediones
8
reverse transcriptase
8
pyrimidinediones non-nucleoside
4
non-nucleoside inhibitors
4
inhibitors hiv-1
4
hiv-1 reverse
4
transcriptase series
4
series n1-heterocyclic
4
pyrimidinediones extensively
4
extensively evaluated
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!